Study of Befotertinib for non-small cell lung cancer with uncommon EGFR mutations
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called Befotertinib for people with non-small cell lung cancer that has uncommon EGFR mutations (like G719X, L861Q, S768I, or exon 20 insertions). It is for those who haven't taken an EGFR-targeted pill before and have had a previous chemotherapy stopped working or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and your daily activity level is reasonably good (ECOG 0-2).
- You have advanced or spread non-small cell lung cancer confirmed by a biopsy.
- Your tumor has a specific uncommon change in the EGFR gene: either G719X, L861Q, S768I, or an insertion in exon 20.
- You have not been treated with a pill that targets EGFR (like osimertinib or erlotinib) before.
- Your cancer worsened or you could not tolerate at least one round of standard platinum chemotherapy.
- You have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted medicines (befotertinib and bevacizumab) before surgery for people with EGFR-mutant non-small cell lung cancer that cannot be removed right away. The goal is to see if this treatment can shrink the tumor and improve surgery outcomes.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
This trial tests a pill called befortinib for people with early-stage lung cancer who have had surgery. It aims to lower the chance of the cancer coming back. You might qualify if your tumor had certain high-risk features and you still have cancer DNA in your blood after surgery.
This study tests a new targeted pill (befotertinib) combined with chemotherapy for people with advanced EGFR-mutated non-small cell lung cancer. The treatment is adjusted based on how well the cancer responds, using a special blood test (MRD) to guide decisions.
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
Hear when a new NSCLC (Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.